Veeva's Submissions & RIM Implemented By Sumitomo Dainippon
Zacks Investment Research | Jun 26, 2019 08:00AM ET
Veeva Systems Inc. (NYSE:VEEV) recently announced that its Vault Submissions and Vault Submissions Archive, implemented by Japan’s Sumitomo Dainippon Pharma, have enabled it to respond faster to health authority requests. Notably, the Vault Submissions and Vault Submissions Archive are part of the Vault RIM Suite. This fortifies Veeva’s foothold in the healthcare IT (HCIT) space.
For investors’ notice, Sumitomo Dainippon Pharma focuses on research and development activities for better healthcare worldwide.
On Vault Submissions & Vault RIM Suite
Veeva Vault Submissions is a unique platform, which creates a single authoritative source for submissions content. This makes storage and processing of data easier for healthcare companies. The platform tracks the progress of documents through actionable reports and dashboards, mitigating risks to submission timelines.
Meanwhile, the Vault RIM Suite is a global source for all regulatory content and product registration data.
It provides unified regulatory information management (RIM) capabilities on a single cloud-based platform including submission document management, product registration management, health authority correspondence and commitments, and submission archiving.
Veeva Systems has experienced robust demand for its Vault platform in recent times. In fact, management at Veeva Systems expects Vault subscription revenues to grow a significant 40% in fiscal 2020.
Product Portfolio Strong
Veeva Systems’ industry-specific focus lends it significant leverage.
The company’s unique solutions include Veeva Vault, Veeva CRM, Veeva Network and VeevaOpenData. Veeva Vault is the first cloud-based content management system built specifically for life sciences. Veeva CRM is a customer relationship management platform that offers cloud-based solutions to reach customers on any channel.
Another new cloud application of the company is Veeva Vault Training, designed to simplify role-based training across life sciences organizations and help quality teams remain audit-ready and compliant.
Market Prospects
BCC Research says that the global market for cloud technologies in healthcare is expected to reach $35 billion by 2022, at a CAGR of 11.6%.
Hence, the latest development has been a profitable one for Veeva.
Price Performance
Buoyed by these solid prospects, this Zacks Rank #2 (Buy) stock has skyrocketed 108.5% compared with the .
DENTSPLY’s long-term earnings growth rate is expected to be 11.5%.
Penumbra’s long-term earnings growth rate is projected at 21.5%.
CONMED’s long-term earnings growth rate is estimated at 13.3%.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Get The News You Want
Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.